<DOC>
	<DOCNO>NCT00228384</DOCNO>
	<brief_summary>To evaluate performance GORE VIABAHN® Endoprosthesis compare bare nitinol stent treatment superficial femoral artery ( SFA ) occlusive disease long lesion .</brief_summary>
	<brief_title>GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study</brief_title>
	<detailed_description>This multicenter , prospective , randomize study clinical radiographic follow-up three year post-procedure . Approximately one hundred fifty subject enrol randomized one two study treatment group .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Lifestylelimiting claudication rest pain . Subject ( legal guardian ) read , understood provide write informed consent . At least 21 year age . Quality life questionnaire complete . Noninvasive low extremity arterial study within 45days prior study procedure . If applicable , stag ipsilateral vascular procedure ≥ 14days prior study procedure . If applicable , vascular treatment nonstudy leg bilateral claudication ≥ 14days prior study procedure . Male , infertile female , female child bear potential practicing acceptable method birth control negative pregnancy test . Projected life expectancy great three year . The ability comply protocol . Angiographic Lesion Requirements meet protocol criterion . Untreated flowlimiting aortoiliac occlusive disease . Any previous stenting surgery target vessel . Subjects arterial lesion require treatment device diameter 6 , 7 , 8 mm . Severe ipsilateral common femoral/profunda disease require surgical intervention . Femoral popliteal aneurysm . Nonatherosclerotic disease result occlusion . Tibial artery disease require treatment . Prior ipsilateral femoral artery bypass . Severe medical comorbidities . Popliteal artery vascular access time procedure . Antegrade retrograde vascular access common femoral artery time SFA intervention . Serum creatinine &gt; 2.5 mg/dL within 45 day prior study procedure . Major distal amputation . Septicemia . Any previously know coagulation disorder . Morbid obesity operative scarring precludes percutaneous approach ( physician 's discretion ) . Contraindication anticoagulation antiplatelet therapy . Known allergy stent/stentgraft component . History prior lifethreatening reaction contrast agent . Currently participate another clinical research trial . Current peritoneal hemodialysis .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>